Tagrisso 2nd Line Program Changes
AstraZeneca is introducing a change to the financial assistance component of the PSP for new patients enrolled after 11:59 pm eastern time Monday, August 27th, 2018.
There is no change for patients enrolled prior to 11:59 pm eastern time Monday, August 27th, 2018. Patients enrolled as per the Health Canada notice of compliance will continue to receive TAGRISSO free of charge for as long as they require treatment with TAGRISSO, either via the PSP or public reimbursement.
New patients enrolled in the PSP after 11:59 pm eastern time Monday, August 27th, 2018 will be eligible for a co-payment towards the cost of the drug; they will not be eligible for drug free of charge.
Patients that have progressed on a first-line TKI and who have a T790M mutation validated test ORDERED prior to11:59 pm eastern time Monday, August 27th, 2018 will be eligible for drug free of charge.
▪ This includes patients who require multiple tests to confirm T790M mutation is present, e.g. negative ctDNA test followed by a tissue biopsy.
▪ Note that a confirmation email to Bayshore from the physician confirming a biopsy (tissue or ctDNA) has been ordered prior to 11:59 pm eastern time Monday, August 27th, 2018 is required.
All existing and new TAGRISSO patients will continue to have access to educational resources, dedicated nurse case managers and support services (e.g., nursing support, referral to patient organizations) to help them during their treatment. Patients accessing TAGRISSO through their private insurance plans will continue to do so.
For additional assistance with enrolling your patients, please contact the AstraZeneca Oncology Patient Support Program at 1-877-280-6208 (available Monday to Friday, from 8:00 AM – 8:00 PM EST).